PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Both yoy net incomes decline, with GNPX at -65.27%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.01%
Less D&A growth vs. GNPX's 7.18%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
9.00%
Less SBC growth vs. GNPX's 165.58%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
715.46%
Well above GNPX's 447.06% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
AP growth well above GNPX's 71.62%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
304.81%
Growth well above GNPX's 234.17%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
412.12%
Some yoy increase while GNPX is negative at -3164.07%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
9.59%
Some CFO growth while GNPX is negative at -22.14%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
Some CapEx rise while GNPX is negative at -231.46%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while GNPX is negative at -203.14%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-4.76%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-85.80%
Both yoy lines negative, with GNPX at -10643.26%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.